291 research outputs found
sj-docx-1-car-10.1177_19476035211053827 – Supplemental material for Retreatment with Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis: Agreement between EUROVISCO Guidelines and Current Medical Practice
No full textSupplemental material, sj-docx-1-car-10.1177_19476035211053827 for Retreatment with Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis: Agreement between EUROVISCO Guidelines and Current Medical Practice by Yves Henrotin, Cedric Tits, Jérôme Paul, Pierre Gramme, Thibault Helleputte, Alberto Migliore, Pascal Richette, Xavier Chevalier, Jordi Monfort, Demirhan Diracoglu, Hervé Bard, Jörg Jerosch, Dominique Baron, Raman Raghu and Thierry Conrozier in CARTILAGE</p
sj-docx-2-car-10.1177_19476035211053827 – Supplemental material for Retreatment with Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis: Agreement between EUROVISCO Guidelines and Current Medical Practice
No full textSupplemental material, sj-docx-2-car-10.1177_19476035211053827 for Retreatment with Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis: Agreement between EUROVISCO Guidelines and Current Medical Practice by Yves Henrotin, Cedric Tits, Jérôme Paul, Pierre Gramme, Thibault Helleputte, Alberto Migliore, Pascal Richette, Xavier Chevalier, Jordi Monfort, Demirhan Diracoglu, Hervé Bard, Jörg Jerosch, Dominique Baron, Raman Raghu and Thierry Conrozier in CARTILAGE</p
Short-Term Risk of Cardiovascular Events in People Newly Diagnosed With Gout
No full textObjectiveTo investigate the temporal association between first diagnosis of gout and cardiovascular events in the short-term.MethodsWe performed a self-controlled case series analysis and a cohort study using data from linked primary care, hospitalisation, and mortality records from the UK's Clinical Practice Research Database (GOLD). We included individuals with a new diagnosis of gout either in the primary care or secondary care between 01/01/1997 and 31/12/2020.The first consultation at which gout was diagnosed was the exposure of interest. The main outcome consisted of cardiovascular events (i.e., a composite of fatal and non-fatal myocardial infarction, ischaemic or haemorrhagic stroke, and transient ischaemic attack).Results4,398 patients (66.9% male, mean age 74.6 years) had a cardiovascular event within ±2 years of their first recorded diagnosis of gout. The incidence of cardiovascular events was significantly higher in the 30 days after the first diagnosis of gout compared to baseline (adjusted incidence rate ratio: 1.55 ((95% confidence interval) 95%CI: 1.33-1.83)).Among 76,440 patients (72.9% male, mean age 63.2 years) included in the cohort study, the incidence of cardiovascular events in the 30 days after the first gout diagnosis (31.2 events/1,000 person-years, 95%CI: 27.1-35.9) was significantly higher than in days 31-730 after gout diagnosis (21.6 events/1,000 person-years, 95%CI:20.8-22.4) with a rate difference of -9.6 events/1,000 person-years, 95%CI: -14.0 to -5.1).ConclusionIndividuals had a short-term increased risk of cardiovascular events in the 30 days following the first consultation at which gout was diagnosed
Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis
No full textpeer reviewedObjectives. The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms
in knee OA.
Methods. Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium
ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee
Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical
improvement (MPCI), minimal clinically important improvement (MCII) and a modified
OMERACT Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew
prematurely from the study were considered non-responders.
Results. There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of
2 g/day, strontium ranelate was associated with greater response than placebo in terms of 520% improvement
in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and 550% improvement
in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for
WOMAC pain (52% vs 40%, P<0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs
37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were
also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment
placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024),
while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months
(P = 0.027 and P = 0.019, respectively).
Conclusion. Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful
improvement in pain from 6 months as well as physical function and stiffness as assessed by the
number of responders above thresholds of clinical relevance
Content alaysis of selected literature relevant to child abuse and self-esteem, 1997
No full textStatement of the Purpose: Selected pertinent literature was examined to see the effects that child abuse had on the self-esteem and psychological development of children. Methodology: A content analysis technique of research was used. Findings: The major finding was that child abuse had negative effects on a childs selfesteem and psychological development. Some effects were longtermed
Faut-il conserver une place à l’acide hyaluronique dans le traitement de la gonarthrose ?
No full text
- …
